Nalbuphine ER · Haduvio

Small molecule

Phase 3underway

Evidence outlook · registrational

Chronic Cough in Idiopathic Pulmonary Fibrosis: registrational readout pending

Its supporting mid-stage studies have completed. ClinicalTrials.gov estimates the registrational readout at 2028-06; company guidance (Trevi Therapeutics, Inc., stated 2026-11-09): topline data expected first half of 2028. The sponsor reported topline results of a Phase 2 study on 2025-06-02 (Phase 2b CORAL of Haduvio (nalbuphine ER) in IPF chronic cough met its primary endpoint); that is not the registrational readout.

Also in development:Prurigo Nodularis · Phase 2/3

Source for the program status

Company guidance: topline data expected second half of 2027 (NCT07868419; Trevi Therapeutics, Inc., 9 Nov 2026). “The 12-week fixed-dose OCEAN-2 trial , was initiated in the third quarter of 2026, and topline results are expected in the second half of 2027.” Source ↗

Company guidance: topline data expected first half of 2028 (NCT07671911; Trevi Therapeutics, Inc., 9 Nov 2026). “The 52-week fixed-dose OCEAN-1 trial was initiated in the second quarter of 2026, and topline results are expected in the first half of 2028.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Chronic Cough in Idiopathic Pulmonary Fibrosis
NCT07868419 · Trevi Therapeutics
2026-09-30 – 2027-10 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 2/3 (1)
Prurigo Nodularis
Phase 2 (4)
Chronic Cough in Idiopathic Pulmonary Fibrosis
NCT05964335 · Trevi Therapeutics
2024-02-06 – 2025-04-24 · Idiopathic Pulmonary Fibrosis
What this study did
NCT04030026 · Trevi Therapeutics
2019-10-29 – 2022-05-27 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07671924 · Trevi Therapeutics
2026-06-22 – 2027-09 · Refractory Chronic Cough
What this study did
NCT05962151 · Trevi Therapeutics
2023-11-30 – 2025-01-06 · Refractory Chronic Cough
What this study did
Phase 1 (5)
Other / comorbidity
NCT07946575 · Trevi Therapeutics
2026-11-03 – 2026-12 · Healthy Participants
What this study did
NCT07036029 · Trevi Therapeutics
2025-08-21 – 2026-06-30 · Idiopathic Pulmonary Fibrosis
What this study did
NCT07487740 · Trevi Therapeutics
2026-02-27 – 2026-05-19 · Healthy Participants
What this study did
NCT07015398 · Trevi Therapeutics
2025-06-30 – 2025-09-26 · Healthy Participants
What this study did
NCT04020016 · Trevi Therapeutics
2019-06-12 – 2020-02-05 · Hepatic Impairment
What this study did

Competitive landscape

This drug's own stage for Prurigo Nodularis: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nalbuphine ER (Haduvio): this drugPhase 2/3Small moleculeKappa-opioid receptor (agonist); mu-opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Nemolizumab (Nemluvio)ApprovedMonoclonal antibodyIL-31 receptor AReliable signalNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)Phase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
StapokibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Haduvio (Nalbuphine ER) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 1Healthy ParticipantsRecruiting
Est. primary completion 2026-11-30 · NCT07946575 · CT.gov ↗
What to watch
2027 (2)
August 2027 (1)
Phase 3Chronic Cough in Idiopathic Pulmonary FibrosisRecruiting
Est. primary completion 2027-08 · NCT07868419 · CT.gov ↗

Company guidance: topline data expected second half of 2027 (Trevi Therapeutics, Inc., 9 Nov 2026). “The 12-week fixed-dose OCEAN-2 trial , was initiated in the third quarter of 2026, and topline results are expected in the second half of 2027.” Source ↗

What to watch
September 2027 (1)
Phase 2Refractory Chronic CoughRecruiting
Est. primary completion 2027-09 · NCT07671924 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 3Chronic Cough in Idiopathic Pulmonary FibrosisRecruiting
Est. primary completion 2028-06 · NCT07671911 · CT.gov ↗

Company guidance: topline data expected first half of 2028 (Trevi Therapeutics, Inc., 9 Nov 2026). “The 52-week fixed-dose OCEAN-1 trial was initiated in the second quarter of 2026, and topline results are expected in the first half of 2028.” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 June 2025Topline resultPhase 2b CORAL of Haduvio (nalbuphine ER) in IPF chronic cough met its primary endpoint
Trevi Therapeutics, Inc. · Source ↗
10 March 2025Topline resultPositive topline results from Phase 2a RIVER trial of Haduvio in RCC